Marc Boutin is deeply involved in health advocacy, policy, and legislation. He has designed and directed numerous strategies for issues ranging from access to health care to cancer prevention. Before joining the National Health Council, he served as the Vice President of Government Relations and Advocacy at the American Cancer Society for New England and was a faculty member at Tufts University Medical School. In addition to senior government relations positions at Easter Seals and the Massachusetts Association of Health Boards, he was a civil rights litigator.
He is a regular spokesperson before the media, Congress, and policy makers on major issues of interest to the patient community.
Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products. At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
PFMD Board Meeting
CORONAVIRUS PREPAREDNESS FOR PEOPLE WITH CHRONIC DISEASES
Webinar on ICER's Value Assessment Framework:
Culture and Process Change as a Priority for Patient Engagement in Medicines Development - Article
12 Jan 2018
Multinational coalition focus on co-creation of meta-framework to benefit patients globally - Video
12 Jan 2018
What do stakeholders expect from patient engagement: Are these expectations being met? - Report
03 Sep 2018
Reasonable agreements between patient advocacy and the pharmaceutical industry - presentation
20 Nov 2018
Reasonable Legal Agreements between Patient Advocates and Pharmaceutical Companies (Leaflet)
20 Mar 2019